Gara Jalqabaatti › Myasthenia Gravis
Qorannoo klinikaalii Myasthenia Gravis Ameerikaa Keessatti hirmaatuu
Qorannoo 45 Myasthenia Gravis f bakka adda addaa Ameerikaa Keessatti hirmaatuu jiru.
Magaalota qorannoo baay'ee qaban
- Tampa, FLQorannoo 12
- Houston, TXQorannoo 11
- Durham, NCQorannoo 10
- Boca Raton, FLQorannoo 10
- Columbus, OHQorannoo 8
- Miami, FLQorannoo 7
- New York City, NYQorannoo 7
- Milwaukee, WIQorannoo 7
- St. Louis, MOQorannoo 7
- Boston, MAQorannoo 6
- Washington, DCQorannoo 6
- San Francisco, CAQorannoo 6
- Orange, CAQorannoo 6
- Philadelphia, PAQorannoo 6
- Columbia, MOQorannoo 6
- Portland, ORQorannoo 6
- Kansas City, KSQorannoo 6
- Austin, TXQorannoo 6
- Chattanooga, TNQorannoo 6
- Jacksonville, FLQorannoo 6
- Dallas, TXQorannoo 6
- Detroit, MIQorannoo 6
- Charleston, SCQorannoo 6
- Aurora, COQorannoo 5
- Lexington, KYQorannoo 5
- Scottsdale, AZQorannoo 5
- Port Charlotte, FLQorannoo 5
- Cincinnati, OHQorannoo 5
- Mountain View, CAQorannoo 4
- Los Angeles, CAQorannoo 4
- Chicago, ILQorannoo 4
- Amherst, NYQorannoo 4
- New Haven, CTQorannoo 4
- Augusta, GAQorannoo 4
- Indianapolis, INQorannoo 3
- Raleigh, NCQorannoo 3
- Knoxville, TNQorannoo 3
- Phoenix, AZQorannoo 3
- Seattle, WAQorannoo 3
- Lansing, MIQorannoo 3
Naannoon
- ArizonaQorannoo 7
- CaliforniaQorannoo 20
- ColoradoQorannoo 8
- ConnecticutQorannoo 6
- Distaarikii KoloombiyaaQorannoo 6
- FloridaQorannoo 22
- GeorgiaQorannoo 4
- IllinoisQorannoo 12
- IndianaQorannoo 3
- KansasQorannoo 7
- KentuckyQorannoo 6
- MassachusettsQorannoo 11
- MichiganQorannoo 12
- MinnesotaQorannoo 3
- MissouriQorannoo 7
- NevadaQorannoo 3
- New JerseyQorannoo 3
- New YorkQorannoo 13
- North CarolinaQorannoo 14
- OhioQorannoo 13
- OregonQorannoo 8
- PennsylvaniaQorannoo 6
- South CarolinaQorannoo 7
- TennesseeQorannoo 10
- TexasQorannoo 18
- VirginiaQorannoo 3
- WashingtonQorannoo 3
- WisconsinQorannoo 7
Qorannoo yeroo dhihootti haaromfaman
Takkalaa qorannoo (Ingiliffa)
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 2 hanga 17 · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT06987539Feasibility of Remote Monitoring of Patients With Myasthenia Gravis
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT07787247Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 hanga 74 · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT07217587A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT07463521A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 hanga 80 · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT07647510ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 24-Ful-2026 · NCT07673627ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 24-Ful-2026 · NCT07294170ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 24-Ful-2026 · NCT07284420A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 24-Ful-2026 · NCT07465289A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07673744Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT06463587A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Ful-2026 · NCT07501702A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 09-Ful-2026 · NCT06680037Zilucoplan for Severe gMG Exacerbations
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Hag-2026 · NCT07215949Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 21-Hag-2026 · NCT06414954AXIS MG Patient Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Hag-2026 · NCT07761026A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 14-Hag-2026 · NCT07304154RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 hanga 70 · Saalaa hunda · Haaromfame 13-Hag-2026 · NCT06359041Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 18 hanga 64 · Dubartoota · Haaromfame 11-Hag-2026 · NCT06940323MuSK Myasthenia 1000 Study
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 7 hanga 99 · Saalaa hunda · Haaromfame 05-Hag-2026 · NCT06259071Study of Aritinercept in Patients With Generalized Myasthenia Gravis
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 hanga 85 · Saalaa hunda · Haaromfame 03-Hag-2026 · NCT07596901A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Namoota walitti qabaa jiraSadarkaa 2/3
Umuriin 2 hanga 17 · Saalaa hunda · Haaromfame 31-Ado-2026 · NCT05265273Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 hanga 80 · Saalaa hunda · Haaromfame 30-Ado-2026 · NCT07039916KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Namoota walitti qabaa jiraSadarkaa 2/3
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 29-Ado-2026 · NCT06193889A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 27-Ado-2026 · NCT04951622Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.